Scientific Advisor’s Nature Study Underscores RECEPTORAI’s Drug Discovery Credentials

According to a recent LinkedIn post from RECEPTORAI, the company highlights that its Chief Scientific Advisor, Dr. Rajiah Aldrin Denny, has coauthored a Nature Communications study on PF-07245303, a dual ITK/TRKA inhibitor originating from his prior work at Pfizer. The post notes that TRKA activity was not an initial design goal but emerged during optimization and was pursued as potentially beneficial polypharmacology for atopic dermatitis.

The LinkedIn post describes reported biochemical data, citing IC50 values of 5.62 nM for ITK and 7.2 nM for TRKA, along with evidence of target engagement in human skin explants. According to the summary, the study indicates inhibition of NGF-induced TRKA phosphorylation and reductions in resident T cell-associated cytokine responses, suggesting a mechanistic rationale for PF-07245303 as a therapeutic candidate in atopic dermatitis.

For investors, the post suggests that RECEPTORAI is closely connected with cutting-edge kinase and dermatology research through its advisory team, which may strengthen its scientific credibility and early-stage deal flow. Association with a Nature Communications publication and with drug discovery experience from a large pharmaceutical company like Pfizer could enhance RECEPTORAI’s positioning when pursuing partnerships, non-dilutive funding, or future capital raises.

While the asset discussed belongs to work conducted at Pfizer and not to RECEPTORAI, the advisory role of Dr. Denny may provide the company with insights into kinase inhibitor design and polypharmacology strategies. This alignment with complex immunology and dermatology mechanisms may be relevant as RECEPTORAI advances or markets its own AI-driven drug discovery capabilities in competitive biotech and pharma service segments.